Prostaglandin E2 primes the angiogenic switch via a synergic interaction with the fibroblast growth factor-2 pathway

Circulation Research

Volumn 105, Issue 7, 2009, Pages 657-666

  Finetti, Federica ^a   Donnini, Sandra ^a   Giachetti, Antonio ^a   Morbidelli, Lucia ^a   Ziche, Marina ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Angiogenesis; Fibroblast growth factor receptor type1; Fibroblast growth factor 2; Inflammation; Prostaglandin E2

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C GAMMA; PROSTAGLANDIN E2; STAT3 PROTEIN; FGFR1 PROTEIN, MOUSE; FRS2ALPHA PROTEIN, MOUSE; MEMBRANE PROTEIN; NOS3 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; CELL CULTURE; CELL PROLIFERATION; CORNEA; ENDOTHELIUM CELL; ENZYME ACTIVATION; EX VIVO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CATTLE; CORNEA NEOVASCULARIZATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; RABBIT; RNA INTERFERENCE; SUBCUTANEOUS TISSUE; TIME; VASCULARIZATION;

ANIMALS; CATTLE; CELL PROLIFERATION; CELLS, CULTURED; CORNEAL NEOVASCULARIZATION; DINOPROSTONE; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; RABBITS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUBCUTANEOUS TISSUE; TIME FACTORS; TRANSFECTION;

EID: 70349682610     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.203760     Document Type: Article

References (36)

1. von Euler US. On the specific vasodilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J Physiol. 1937;88:213-234.
2. Wang MT, Honn KV, Nie D. Cyclooxygenase, prostanoids and tumor progression. Cancer Metastasis Rev. 2007;26:525-534.
3. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massagué J. Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. Nature. 2007;446: 765-771.
4. Chang S-H, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A. 2004;101:591-596.
5. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp. 1991;22:339-347.
6. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem. 2008;283:2139-2146.
7. Schelling ME, Meininger CJ, Hawker JR Jr, Granger HJ. Venular endo-thelial cells from bovine heart. Am J Physiol. 1988;254:H1211-H1217.
8. Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Molinari-Tosatti MP, Bonardi F, Parolini S, Albini A, Morbidelli L, Ziche M, Corallini A, Possati L, Vacca A, Ribatti D, Presta M. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ. 1996;7:147-160.
9. Yu P-J, Ferrari G, Galloway AC, Mignatti P, Pintucci G. Thrombin cleaves the high molecular weight forms of basic fibroblast growth factor (FGF-2): a novel mechanism for the control of FGF-2 and thrombin activity. Oncogene. 2008;27:2594-2601.
10. Fisslthaler B, Loot AE, Mohamed A, Busse R, Fleming I. Inhibition of endothelial nitric oxide synthase activity by proline-rich tyrosine kinase 2 in response to fluid shear stress and insulin. Circ Res. 2008;102: 1520-1528.
11. Donnini S, Finetti F, Solito R, Terzuoli E, Sacchetti A, Morbidelli L, Patrignani P, Ziche M. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transacti-vation and iNOS and ERK1/2 pathways. FASEB J. 2007;21:2418-2430.
12. Passaniti A. Extracellular matrix-cell interactions: Matrigel and complex cellular pattern formation. Lab Invest. 1992;67:804.
13. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endo-thelium growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-2634. (Pubitemid 27259809)
14. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG. Angiopoietin-2 sensitizes en-dothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235-239.
15. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039-2049.
16. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Andras N, Roos KP, Iruela-Arispe M. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130:691-703.
17. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61:203-212.
18. Murakami M, Nguyen LT, Zhang ZW, Moodie KL, Carmeliet P, Stan RV, Simons M. The FGF system has a key role in regulating vascular integrity. J Clin Invest. 2008;118:3355-3366.
19. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis. Signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22:201-207.
20. Cross MJ, Lu L, Magnusson P, Nyqvist D, Holmqvist K, Welsh M, Claesson-Welsh L. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phos-phorylation in endothelial cells. Mol Biol Cell. 2002;13:2881-2893.
21. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM. Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol. 1999; 154:937-944.
22. Zeng ZZ, Yellaturu CR, Neeli I, Rao GN. 5(S)-hydroxyeicosatetraenoic acid stimulates DNA synthesis in human microvascular endothelial cells via activation of Jak/STAT and phosphatidylinositol 3-kinase/Akt signaling, leading to induction of expression of basic fibroblast growth factor 2. J Biol Chem. 2002;25;277:41213-41219.
23. Voisine P, Li J, Bianchi C, Khan TA, Ruel M, Xu SH, Feng J, Rosinberg A, Malik T, NaKai Y, Sellke FW. Effects of L-arginine on fibroblast growth factor 2-induced angiogenesis in a model of endothelial dysfunction. Circulation. 2005;112(suppl I):I-202-I-207.
24. Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R, Breyer MD, Pozzi A. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem. 2007;282: 16959-16968.
25. Cao H, Dronadula N, Rizvi F, Li Q, Srivastava K, Gerthoffer WT, Rao GN. Novel role for STAT-5B in the regulation of Hsp27-FGF-2 axis facilitating thrombin-induced vascular smooth muscle cell growth and motility. Circ Res. 2006;98:913-922.
26. Alfranca A, López-Oliva JM, Genís L, López-Maderuelo D, Mirones I, Salvado D, Quesada AJ, Arroyo AG, Redondo JM. PGE2 induces angio-genesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood. 2008;112:1120-1128.
27. Presta M, Dell?Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159-178.
28. Murakami M, Elfenbein A, Simons M. Non-canonical fibroblast growth factor signalling in angiogenesis. Cardiovasc Res. 2008;78:223-231.
29. Li J, Partovian C, Li J, Hampton TG, Metais C, Tkachenko E, Sellke FW, Simons M. Modulation of microvascular signaling by heparan sulfate matrix: studies in syndecan-4 transgenic mice. Microvasc Res. 2002;64: 38-46.
30. Mazar-Feldman J, Rimon G. A common low-affinity binding site for primary prostanoids on bovine aortic endothelial cells. Cell Signal. 1996; 8:497-501.
31. Lu H, Xu X, Zhang M, Cao R, Bråkenhielm E, Li C, Lin H, Yao G, Sun H, Qi L, Tang M, Dai H, Zhang Y, Su R, Bi Y, Zhang Y, Cao Y. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc Natl Acad Sci U S A. 2007;104:12140-12145.
32. Deindl E, Hoefer IE, Fernandez B, Barancik M, Heil M, Strniskova M, Schaper W. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis. Circ Res. 2003;92: 561-568.
33. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst. 1982;69:475-482.
34. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A. 2006;103:1492-1497.
35. Chen L, He Y, Huang H, Liao H, Wei W. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Med Oncol. 2008;25:161-171.
36. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008;68:1213-1220.